These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16338390)

  • 1. Quantitative assays of Mdm2 ubiquitin ligase activity and other ubiquitin-utilizing enzymes for inhibitor discovery.
    Auger KR; Copeland RA; Lai Z
    Methods Enzymol; 2005; 399():701-17. PubMed ID: 16338390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.
    Lai Z; Yang T; Kim YB; Sielecki TM; Diamond MA; Strack P; Rolfe M; Caligiuri M; Benfield PA; Auger KR; Copeland RA
    Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14734-9. PubMed ID: 12407176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.
    Herman AG; Hayano M; Poyurovsky MV; Shimada K; Skouta R; Prives C; Stockwell BR
    Cancer Discov; 2011 Sep; 1(4):312-25. PubMed ID: 22586610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity.
    Ranaweera RS; Yang X
    J Biol Chem; 2013 Jun; 288(26):18939-46. PubMed ID: 23671280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Characterization of Physiological Pairing of E2 Ubiquitin-Conjugating Enzymes and E3 Ubiquitin Ligases.
    Brillada C; Trujillo M
    Methods Mol Biol; 2023; 2581():13-29. PubMed ID: 36413307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
    Wei J; Yang Y; Lu M; Xu L; Liu F; Yuan Z; Bao Q; Jiang Z; Xu X; Guo X; Zhang X; You Q; Sun H
    Anticancer Agents Med Chem; 2015; 16(2):174-89. PubMed ID: 26343143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MALDI-TOF E2/E3 Ligase Assay as Universal Tool for Drug Discovery in the Ubiquitin Pathway.
    De Cesare V; Johnson C; Barlow V; Hastie J; Knebel A; Trost M
    Cell Chem Biol; 2018 Sep; 25(9):1117-1127.e4. PubMed ID: 30017913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 Ubiquitination and proteasomal degradation.
    Love IM; Shi D; Grossman SR
    Methods Mol Biol; 2013; 962():63-73. PubMed ID: 23150437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction.
    Gao K; Wang C; Jin X; Xiao J; Zhang E; Yang X; Wang D; Huang H; Yu L; Zhang P
    Cancer Lett; 2016 May; 375(1):133-141. PubMed ID: 26926424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
    Honda R; Tanaka H; Yasuda H
    FEBS Lett; 1997 Dec; 420(1):25-7. PubMed ID: 9450543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting Hdm2 and ubiquitin-activating enzyme: targeting the ubiquitin conjugating system in cancer.
    Weissman AM; Yang Y; Kitagaki J; Sasiela CA; Beutler JA; O'Keefe BR
    Ernst Schering Found Symp Proc; 2008; (1):171-90. PubMed ID: 19202599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
    Clegg HV; Itahana Y; Itahana K; Ramalingam S; Zhang Y
    PLoS One; 2012; 7(5):e38212. PubMed ID: 22666487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization.
    Lai Z; Ferry KV; Diamond MA; Wee KE; Kim YB; Ma J; Yang T; Benfield PA; Copeland RA; Auger KR
    J Biol Chem; 2001 Aug; 276(33):31357-67. PubMed ID: 11397792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity.
    Kawai H; Lopez-Pajares V; Kim MM; Wiederschain D; Yuan ZM
    Cancer Res; 2007 Jul; 67(13):6026-30. PubMed ID: 17616658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4.
    Marcar L; Ihrig B; Hourihan J; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Hupp TR; Meek DW
    PLoS One; 2015; 10(5):e0127713. PubMed ID: 26001071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Analysis of E3 Ubiquitin Ligase Function.
    Müller L; Kutzner CE; Balaji V; Hoppe T
    J Vis Exp; 2021 May; (171):. PubMed ID: 34057440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity.
    Chinnam M; Xu C; Lama R; Zhang X; Cedeno CD; Wang Y; Stablewski AB; Goodrich DW; Wang X
    PLoS Genet; 2022 May; 18(5):e1010171. PubMed ID: 35588102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribosomal protein S7 is both a regulator and a substrate of MDM2.
    Zhu Y; Poyurovsky MV; Li Y; Biderman L; Stahl J; Jacq X; Prives C
    Mol Cell; 2009 Aug; 35(3):316-26. PubMed ID: 19683495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a Catalytic Active but Non-Aggregating MDM2 RING Domain Variant.
    Magnussen HM; Huang DT
    J Mol Biol; 2021 Mar; 433(5):166807. PubMed ID: 33450248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-throughput screen measuring ubiquitination of p53 by human mdm2.
    Murray MF; Jurewicz AJ; Martin JD; Ho TF; Zhang H; Johanson KO; Kirkpatrick RB; Ma J; Lor LA; Thrall SH; Schwartz B
    J Biomol Screen; 2007 Dec; 12(8):1050-8. PubMed ID: 17989425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.